Ignite Creation Date:
2024-05-05 @ 11:26 AM
Last Modification Date:
2024-10-26 @ 9:07 AM
Study NCT ID:
NCT00040547
Status:
COMPLETED
Last Update Posted:
2015-02-18
First Post:
2002-06-28
Brief Title:
Farnesyl Protein Transferase Inhibitor FPTI in Combination With Docetaxel in Advanced Solid Tumors Study P01964COMPLETED
Sponsor:
Merck Sharp Dohme LLC
Organization:
Merck Sharp Dohme LLC
Study Overview
Official Title:
Safety and Tolerability Study of Farnesyl Protein Transferase Inhibitor FPTI in Combination With Docetaxel in Advanced Solid Tumors
Status:
COMPLETED
Status Verified Date:
2015-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine the safety and tolerability of an oral Farnesyl Protein Transferase Inhibitor SCH 66336 when given in combination with intravenous docetaxel in cancer patients with advanced solid tumors
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None